Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares

Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease. The post Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares appeared first on Investor's Business Daily.